Mirum Pharmaceuticals scored major momentum for its hepatitis delta portfolio, landing a U.S. FDA approval for its once-daily, oral ALK2 inhibitor Atebrioz (zilurgisertib) as the company positions for broader commercial uptake. The company also disclosed Phase 3 data for brelovitug, reporting a positive virologic response and ALT normalization primary endpoint in a recently acquired program.